GSK PLC Sponsored ADR $GSK Shares Sold by Synovus Financial Corp

Key Points

• Synovus Financial Corp reduced its shares in GSK PLC by 16.6% in the first quarter, now holding 141,027 shares valued at approximately $5.46 million.
• Hedge funds have variedly adjusted their positions in GSK, with Dodge & Cox increasing its stake by 14.9% while Voloridge Investment Management boosted its holdings by an impressive 1,360.4%.
• Several research firms have recently altered their ratings on GSK, with consensus reflecting a "Reduce" rating and a price target of $37.38.

Synovus Financial Corp decreased its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 16.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 141,027 shares of the pharmaceutical company's stock after selling 28,055 shares during the quarter. Synovus Financial Corp's holdings in GSK were worth $5,463,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of GSK. Dodge & Cox grew its holdings in GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares during the last quarter. Primecap Management Co. CA grew its holdings in GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock valued at $995,929,000 after purchasing an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company's stock valued at $299,163,000 after purchasing an additional 155,392 shares during the last quarter. Equity Investment Corp grew its holdings in GSK by 5.3% in the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock valued at $161,708,000 after purchasing an additional 211,608 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in GSK by 0.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock valued at $87,884,000 after purchasing an additional 18,492 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Trading Up 0.6%

Shares of GSK stock traded up $0.24 during trading hours on Friday, reaching $39.68. The stock had a trading volume of 2,986,753 shares, compared to its average volume of 5,096,452. The firm has a market capitalization of $80.82 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 1.73 and a beta of 0.51. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.26. The firm has a 50 day simple moving average of $38.37 and a two-hundred day simple moving average of $38.20.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same period in the previous year, the business earned $0.43 EPS. GSK's revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is 77.78%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GSK shares. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.